Pafuramidine is a novel orally active antimalarial. To identify a combination partner, we measured the in vitro antimalarial activities of the active metabolite, DB75, with amodiaquine, artemisinin, atovaquone, azithromycin, chloroquine, clindamycin, mefloquine, piperaquine, pyronaridine, tafenoquine, and tetracycline. None of the drugs tested demonstrated antagonistic or synergistic activity i...

Piperaquine is being developed as a long-acting component in artemisinin combination therapies. It was highly active in vitro and drug interaction studies showed that dihydroartemisinin combinations with piperaquine, chloroquine, and amodiaquine were indifferent tending toward antagonism. Competitive uptake of radiolabeled chloroquine and dihydroartemisinin in combination with other antimalaria...

GENERIC NAME PAGE Amodiaquine 614 Atovaquone 616 Chloroguanide 615 Chloroquine 613 Dapsone 615 Diloxanide 609 Eflornithine 610 Hydroxychloroquine 614 Iodoquinol 608 Mefloquine 616 Meglumine antimonate 611 Melarsoprol 610 GENERIC NAME PAGE Metronidazole 608 Nifurtimox 610 Paromomycin 609 Pentamidine 609 Primaquine 614 Pyrimethamine 614 Quinine 615 Sodium stibogluconate 611 Suramin 609 Trimethopr...

National malaria management policy is based upon the availability of effective and affordable antimalarial drugs. This study was undertaken to evaluate the quality of the treatment of uncomplicated malaria cases in Bangui, an area with multi-drug resistant parasites, at a time preceding implementation of a new therapeutic policy relying on the artemisinin derivative combined treatment artemethe...

The Republic of the Congo adopted artemisinin-based combination therapies (ACTs) in 2006: artesunate-amodiaquine and artemether-lumefantrine as the first-line and second-line drugs, respectively. The baseline efficacy of artemether-lumefantrine was evaluated between March and July 2006 in Brazzaville, the capital city of Congo. Seventy-seven children aged between 6 months and 10 years were enro...

Background. In Cameroon, both Artesunate-amodiaquine (AS/AQ) and artemether-lumefantrine (AL) are used as first-line treatment against uncomplicated malaria in line with the WHO recommendations. We compared the efficacy and safety of both therapeutic combinations and determined the prevalence of drug resistance conferring mutations in three parasite genes. Methods. One hundred and fifty acute m...

Correspondence A. Sowunmi Department of Clinical Pharmacology University College Hospital Ibadan, Nigeria E-mail: [email protected] Fax: +234-2-2411843 Tel: 234-2 2412101 AC CE PT ED Copyright © 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. Antimicrob. Agents Chemother. doi:10.1128/AAC.00077-07 AAC Accepts, published online ahead of p...